Your browser doesn't support javascript.
loading
Therapeutic use of carbohydrate-restricted diets in an autistic child; a case report of clinical and 18FDG PET findings.
Zarnowska, Iwona; Chrapko, Beata; Gwizda, Grazyna; Nocun, Anna; Mitosek-Szewczyk, Krystyna; Gasior, Maciej.
Afiliação
  • Zarnowska I; Department of Pediatric Neurology, Gebali 6, 20-093, Lublin, Poland.
  • Chrapko B; Department of Nuclear Medicine, Jaczewskiego 8c, 20-090, Lublin, Poland.
  • Gwizda G; Department of Pediatric Otolaryngology, Phoniatry and Audiology, Gebali 6, 20-093, Lublin, Poland.
  • Nocun A; Department of Nuclear Medicine, Jaczewskiego 8c, 20-090, Lublin, Poland.
  • Mitosek-Szewczyk K; Department of Pediatric Neurology, Gebali 6, 20-093, Lublin, Poland.
  • Gasior M; Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, USA. NextPharma@gmail.com.
Metab Brain Dis ; 33(4): 1187-1192, 2018 08.
Article em En | MEDLINE | ID: mdl-29644487
The ketogenic diet (KD) is a high-fat, adequate-protein, and low-carbohydrate diet that has been used successfully in the treatment of refractory epilepsies for almost 100 years. There has been accumulating evidence to show that the KD may provide a therapeutic benefit in autism spectrum disorders, albeit by a yet-unknown mechanism. We report a case of a 6-year-old patient with high-functioning autism and subclinical epileptic discharges who responded poorly to several behavioural and psychopharmacological treatments. The patient was subsequently placed on the KD due to significant glucose hypometabolism in the brain as revealed by an 18FDG PET. As soon as one month after starting the KD, the patient's behavior and intellect improved (in regard to hyperactivity, attention span, abnormal reactions to visual and auditory stimuli, usage of objects, adaptability to changes, communication skills, fear, anxiety, and emotional reactions); these improvements continued until the end of the observation period at 16 months on the KD. The 18FDG PET, measured at 12 months on the KD, revealed that 18F-FDG uptake decreased markedly and diffusely in the whole cerebral cortex with a relatively low reduction in basal ganglia in comparison to the pre-KD assessment. It warrants further investigation if the 18FDG PET imaging could serve as a biomarker in identifying individuals with autism who might benefit from the KD due to underlying abnormalities related to glucose hypometabolism.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtorno Autístico / Encéfalo / Dieta Cetogênica Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Child / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtorno Autístico / Encéfalo / Dieta Cetogênica Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Child / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article